MariMed (MRMD) CFO reports RSU vesting and tax-related share withholding

Rhea-AI Filing Summary

MariMed Inc. Chief Financial Officer Mario Pinho reported routine equity award activity. On January 15, 2026, 49,995 restricted stock units converted into 49,995 shares of common stock at a price of $0 per share, increasing his directly held common stock to 294,809 shares. As part of the same vesting event, 17,324 common shares were withheld by MariMed at $0.096 per share to satisfy tax withholding obligations, leaving Pinho with 277,485 common shares held directly after the withholding.

The underlying restricted stock unit award was originally granted on July 15, 2024 and continues to vest over time, with remaining installments scheduled on July 15, 2026, January 15, 2027 and July 15, 2027. Following this transaction, Pinho directly holds 149,985 restricted stock units, each convertible into one share of common stock.

Insights

Equity compensation analyst

Routine RSU vesting and tax withholding by MariMed’s CFO.

MariMed’s Chief Financial Officer, Mario Pinho, reported the vesting of 49,995 restricted stock units on January 15, 2026, which converted one-for-one into common shares at an exercise price of $0. This is standard for RSUs, which typically convert without a cash payment when vesting conditions are met.

To cover tax obligations from this vesting, the issuer withheld 17,324 common shares at $0.096 per share, a common practice instead of using cash. After these events, Pinho directly holds 277,485 common shares and 149,985 RSUs that will continue to vest in three installments on July 15, 2026, January 15, 2027, and July 15, 2027. These are typical administrative equity-compensation transactions, with no clear signal of a discretionary open-market sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinho Mario

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	01/15/2026		M		49,995	A	$0(1)	294,809	D
Common stock	01/15/2026		F		17,324(2)	D	$0.096	277,485	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	01/15/2026		M			49,995	(3)	(3)	Common Stock, par value $.001 per share	49,995	$0	149,985	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. The RSUs were granted on July 15, 2024; the remaining RSUs under this grant will vest in three equal installments, on each of July 15, 2026, January 15, 2027 and July 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Mario Pinho	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) report for its CFO on January 15, 2026?

MariMed’s Chief Financial Officer, Mario Pinho, reported the vesting of 49,995 restricted stock units that converted into 49,995 common shares on January 15, 2026, at a price of $0 per share.

How many MariMed (MRMD) shares were withheld for taxes in this Form 4 filing?

The filing shows that 17,324 shares of common stock were withheld by MariMed at $0.096 per share to satisfy tax withholding obligations related to the RSU vesting.

How many MariMed (MRMD) common shares does the CFO hold after this transaction?

After the RSU conversion and tax share withholding, Chief Financial Officer Mario Pinho directly holds 277,485 shares of MariMed common stock.

How many restricted stock units does the MariMed (MRMD) CFO still own after this Form 4?

Following the reported transactions, Mario Pinho directly holds 149,985 restricted stock units, each convertible into one share of MariMed common stock.

When will the remaining MariMed (MRMD) RSUs for the CFO vest?

The remaining RSUs from the July 15, 2024 grant will vest in three equal installments on July 15, 2026, January 15, 2027 and July 15, 2027, according to the award agreement.

Was there a cash exercise price for the MariMed (MRMD) CFO’s RSU conversion?

No. The restricted stock units converted to common stock at an exercise price of $0 per share, which is typical for RSU vesting.